Sleep and Pain Interventions in Women With Fibromyalgia

Fibromyalgia Clinical Trial

— SPIN-II  

Official title:

Impact of CBT for Insomnia on Pain Symptoms and Central Sensitization in Fibromyalgia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03744156
• Other study ID #: 2011835
• Secondary ID: 1R01NR017168-01A
• Status: Recruiting
• Phase: N/A
• Start date: February 7, 2019
• Est. completion date: May 31, 2025

Study information

• Verified date: June 2024
• Source: University of Missouri-Columbia
• Contact: Austin D Ohley, BS
• Phone: (573) 882-5113
• Email: ajobzr[@]health.missouri.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Insomnia affects 67-88% of chronic pain patients. SPIN II is a randomized controlled clinical trial that will compare the effects of two cognitive behavioral sleep treatments in women with fibromyalgia and insomnia. This trial will yield important information about the roles of sleep, arousal, and brain structure and function in the development and maintenance of chronic pain in women with fibromyalgia.

Description:

This mechanistic trial will assess sleep, pain, arousal, and neural imagining outcomes at baseline, post-8 week behavioral treatment (CBT-I or SHE), as well as at 6 and 12 month followups. This information will provide novel information about the neural structures and functional networks associated with chronic pain, and their manipulation through a cognitive behavioral intervention to improve insomnia. Demonstration that a relatively brief intervention can reverse or resolve pain related maladaptive neural plasticity, and improve or resolve clinical pain symptoms would have immediate and far-reaching implications for millions of chronic pain sufferers as well as for the US healthcare system and economy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 130
• Est. completion date: May 31, 2025
• Est. primary completion date: March 31, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• female

• 18+ years of age

• willing to be randomized

• can read and understand English

• diagnosed with Fibromyalgia and insomnia

• no prescript or over the counter pain or sleep medicaments for 1+ month

Exclusion Criteria:

• unable to provide informed consent

• cognitive impairment

• sleep disorder other than insomnia (i.e., sleep apnea, periodic limb movement disorder

• bipolar or seizure disorder

• other major psychopathology (other than depression or anxiety)

• psychotropic or other medications that alter pain or sleep

• participation in non-pharmacological treatment (including CBT) for pain, sleep, or mood outside current trial

• internal metal objects or electrical devices

• pregnancy

Related Conditions & MeSH terms

• Chronic Widespread Pain
• Fibromyalgia
• Insomnia
• Myofascial Pain Syndromes
• Sleep Initiation and Maintenance Disorders

Intervention

Behavioral:
• Cognitive Behavioral Treatment-Insomnia
8 session Cognitive Behavioral Therapy for Insomnia. Individualized sessions with a therapist.
• Sleep Hygiene Education
8 Session Sleep Hygiene Education. Individualized sessions with a therapist.

Locations

Country	Name	City	State
United States	University of Missouri- Department of Psychiatry	Columbia	Missouri

Sponsors (3)

Lead Sponsor	Collaborator
University of Missouri-Columbia	National Institute of Nursing Research (NINR), University of Florida

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Self-Reported Bedtime, Wake time, Sleep Onset Latency, Wake After Sleep Onset, Sleep Quality on the Daily Diaries	Participants will answer the following questions on the daily diaries: I napped for ____________ minutes yesterday. I napped ______ times yesterday. I napped in the ___morning ___afternoon ____evening (check all that apply) I went to bed last night at ____________ AM/PM. It took me ____________ minutes to fall asleep. I woke up ____________ times last night. I was awake for ____________ minutes in the middle of the night. My final wake up time was ____________ AM/PM. I got out of bed at ____________ AM/PM. I would rate my quality of sleep last night as ____________.; 1. very poor 2. poor 3. fair. 4 good 5. Excellent	baseline to follow-up (approximately 60 weeks)
Primary	Change in Insomnia Severity Index (ISI)	The Insomnia Severity Index will be administered four times - baseline, post-treatment, and 6 and 12 month follow-up. Analysis will involve examining the trend of change in the ISI.	baseline to follow-up (approximately 60 weeks)
Primary	Change in Peripheral Arousal	heart rate variability (as measured by Holter-Monitoring)	baseline to follow-up (approximately 60 weeks)
Primary	Change in Perceived Stress Scale	measures how much self-reported stress participants experience (from 0-never to 4-very often) across various 10 situations. Higher total scores indicate greater perceived stress.	baseline to follow-up (approximately 60 weeks)
Primary	Change in Dysfunctional Beliefs and Attitudes about Sleep (DBAS)	30-item self-report questionnaire designed to identify and assess various sleep/insomnia-related cognitions (e.g., beliefs, attitudes, expectations, appraisals, attributions).	baseline to follow-up (approximately 60 weeks)
Primary	Change in Pain Catastrophizing Scale	The PCS instructions ask participants to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the end points (0) not at all and (4) all the time. The PCS yields a total score and three subscale scores assessing rumination, magnification and helplessness. Total score range from 0-52, with higher scores indicating greater pain catastrophizing.	baseline to follow-up (approximately 60 weeks)
Primary	Change in self-reported ratings of Pain Sensitivity and Pain Unpleasantness on Daily Diaries	Participants will rate how much pain they experience and how unpleasant the pain is on a scale of 1 to 100 on the daily dairies. Analysis will involve examining the trend of changes in these ratings.	baseline to follow-up (approximately 60 weeks)
Primary	Neural Imaging: Structural/Functional MRI/Diffusion Weighted Imaging	assessment of neural plasticity	baseline to follow-up (approximately 60 weeks)
Primary	Change in Bedtime, Wake time, Sleep Onset Latency, and Wake After Sleep Onset measured by Actigraphy	Actiwatch-L (ACT-L; Mini Mitter, Inc.) will be used to obtain a behavioral measure of sleep outcome. ACT-L is a wristwatch-like device that provides long-term monitoring of ambient light exposure and gross motor activity in human subjects. The Actiware-Sleep software provides behavioral estimates for several sleep variables: (1) sleep onset latency-interval between bedtime and sleep start; (2) total sleep time-sum of all sleep epochs within the sleep period; (3) sleep efficiency percentage- ratio of total sleep time to total time spent in bed × 100; and (4) total wake time-sum of all wake epochs within the sleep period.	baseline to follow-up (approximately 60 weeks)
Primary	Change in Thermal Pain Response	Participants will undergo quantitative sensory testing using a contact thermode applied to the volar surface of the forearm. The protocol that will assess both first pain (primarily A-delta function) and second pain (primarily C-fiber input). All thermal stimuli will be delivered using a computer-controlled Medoc Thermal Sensory Analyzer (TSA-2001, Ramat Yishai, Israel).; Visual Analog Scale (VAS) ratings of 4 graded intensities (45, 47, 49, 51° C) of 5 second temperature stimuli will be obtained in the following fashion: Stimulus presentation will be timed such that no site is stimulated with less than a 3-minute interval to avoid sensitization of the site. Participants will rate 8 stimuli (2 at each intensity) using a VAS for pain intensity anchored at the right end by "the most intense pain imaginable." A second random sequence of 8 stimuli (2 at each intensity) will be rated by VAS for pain unpleasantness.	baseline to follow-up (approximately 60 weeks)
Secondary	Polysomnographically assessed sleep onset, wake time after sleep onset, sleep efficiency, number of awakenings, total sleep time, and sleep stage %.	Ambulatory Polysomnography will be conducted four times at baseline, post-treatment, 6-month, and 12 month follow-up. This involves attachment of small electrodes and wires to the head and body.	baseline to follow-up (approximately 60 weeks)
Secondary	Change in pain severity assessed by the McGill Pain Questionnaire	The McGill Pain Questionnaire will be administered four times - baseline, post-treatment, 6 month and 12 month follow-up. Analysis will involve examining the trend of change in the scores in McGill Pain Questionnaire.	baseline to follow-up (approximately 60 weeks)
Secondary	Change in pain-associated disability assessed by the Pain Disability Questionnaire	The Pain Disability Questionnaire will be administered four times - baseline, post-treatment, 6 month follow-up and 12-month follow-up. Analysis will involve examining the trend of change in the scores in Pain Disability Questionnaire.	baseline to follow-up (approximately 60 weeks)
Secondary	Change in Beck Depression Inventory-Second Edition	This 21-item scale measures self-reported depressive symptoms. Total scores range from 0-63, with higher scores indicating greater maladjustment.	baseline to follow-up (approximately 60 weeks)
Secondary	Change in State-Trait Anxiety Inventory-Form Y1 (STAI-YI)	The STAI-Y1 contains 20 items for assessing trait anxiety and 20 for state anxiety. State anxiety items include: "I am tense; I am worried" and "I feel calm; I feel secure." Trait anxiety items include: "I worry too much over something that really doesn't matter" and "I am content; I am a steady person." All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Higher scores indicate greater anxiety.	baseline to follow-up (approximately 60 weeks)
Secondary	Change in Pain Anxiety Symptoms Scale	A 20 item self-report scale that measures the frequency (0-never, to 5-almost always) of anxiety across situations in which pain is experienced. Total scores range from 0 to 100 with higher scores indicating greater anxiety related to pain.	baseline to follow-up (approximately 60 weeks)
Secondary	Change in Anxiety and Preoccupation about Sleep Questionnaire	A 10-item scale that asks participants to rate the level of worry and/or anxiety during several situations regarding disturbed sleep. Participant rate the truthfulness of each statement according to their own experience (1-not true to 10-very true). Higher total scores indicate greater anxiety/preoccupation about sleep.	baseline to follow-up (approximately 60 weeks)
Secondary	Activities of Daily Living (ADL) - Katz ADL Scale	A 6-item scale that measures the degree of independence on activities of daily living (1-independent; 0-dependent; activities include bathing, dressing, toileting, transferring, continence and feeding). Higher total scores indicate greater degree of independence on ADLs	baseline to post-treatment (approximately 12 weeks)
Secondary	Independent Activities of Daily Living (IADL) - Lawton IADL Scale	A 8-item scale that measures the degree of independence in performing instrumental activities of daily living (1-independent; 0-dependent; instrumental daily activities include ability to use telephone, shopping, food preparation, housekeeping, laundry, transportation, responsibility for own medications, and finances). Higher total scores indicate greater degree of independence on IADLs	baseline to post-treatment (approximately 12 weeks)
Secondary	Cognitive Failures Questionnaire	A 25-item scale measuring subjective cognition; caregivers rate on a scale of 0 (never) to 4 (very often) how often they experience cognitive mistakes and errors in daily tasks	baseline to post-treatment (approximately 12 weeks)
Secondary	Cognition - NIH Toolbox	A 20-minute computerized battery completed in a single setting on iPad (20 in. screen); domains tested include processing speed and attention, visuospatial ability and memory, verbal learning and memory, and executive functioning and working memory	baseline to post-treatment (approximately 12 weeks)
Secondary	Hair Sample	A sample of hair (cut, not extracted/no hair bulb) will be analyzed for the inflammatory and stress hormone cortisol	baseline to post-treatment (approximately 12 weeks)
Secondary	Saliva Sample	A sample of saliva will be analyzed to determine if the APOE-4 genetic marker is present.	baseline to post-treatment (approximately 12 weeks)
Secondary	Biomarkers - Neurodegeneration and Inflammation	Blood based biomarkers and hormones will be examined at each assessment period; biomarkers include CRP & IL-6, AßB42, AßB40 & total tau and phosphorylated-Tau at threonine181 & threonine217	baseline to post-treatment (approximately 12 weeks)
Secondary	Plasma-Based Hormones	Blood plasma analysis of three hormones including estradiol, testosterone, and cortisol	baseline to post-treatment (approximately 12 weeks)
Secondary	Global Cognition - Mini Mental Status Exam (MMSE)	An 11-item questionnaire that provides a measure of global cognition. Participants are asked questions related to orientation to time/place, memory immediate/ delayed recall, attention and calculation, naming, repetition, comprehension, reading, writing, and drawing. Participants are scored 0-incorrect or 1- correct on each item. Total score is computed (out of 30), with higher total scores indicating better global cognitive function.	baseline to follow-up (approximately 60 weeks)
Secondary	Global Cognition - Montreal Cognitive Assessment (MoCA)	A 30-item questionnaire that provides a measure of global cognition. Participants are asked questions related to visuospatial/executive functioning, naming, memory immediate/delayed recall, attention, language, abstraction, and orientation to time/place. Participants are scored 0-incorrect or 1-correct on each item. Total score is computed (out of 30), with higher total scores indicating better global cognitive function.	baseline to post-treatment (approximately 12 weeks)